ArticleClinical ophthalmology (Auckland, N.Z.)2026
Region-Specific Retinal and Choroidal Biomarkers Associated with Visual Outcomes After Anti-VEGF Treatment in Center-Involved Diabetic Macular Edema.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This investigation sought to: (1) characterize anti-vascular endothelial growth factor (VEGF) therapy-induced choroidal structural modifications in center-involved diabetic macular edema (CI-DME) utilizing swept-source optical coherence tomography (SS-OCT) imaging, and (2) assess the predictive capacity of choroidal morphometric indices for visual functional prognosis. Methods and Analysis: This retrospective cohort study encompassed CI-DME patients received intravitreal anti-VEGF injections. Structural parameters, including retinal thickness, choroidal thickness, and choroidal vascularity index (CVI), were measured by SS-OCT pre- and post-treatment. Statistical evaluations included paired t-tests, Wilcoxon tests, Elastic Net regression, sensitivity analyses and prognostic analysis. Subgroup analysis was stratified by baseline characteristics. Results: 58 eyes from 53 CI-DME patients were included. Following a single dose of anti-VEGF injection, logMAR BCVA improved significantly from 0.694 ± 0.342 to 0.614 ± 0.429 ( Conclusion: SS-OCT imaging revealed region-specific changes of the retinal and choroidal thickness after anti-VEGF treatment, providing a practical reference for monitoring and tracking therapeutic response in CI-DME.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.